Article
Look out, Regeneron. As the threat from Roche's Vabysmo grows, one team of analysts slashes its Eylea sales estimate
Rating:
0.0
Views:
69
Likes:
1
Library:
1
Regeneron's Eylea has long dominated the ophthalmology market thanks to its strong efficacy and safety profile. But its unquestioned run at the top now appears under threat. | Doubts about the ability of Regeneron to succeed in phase 3 trials of its high-dose version of Eylea and growing confidence in Roche's newly-approved challenger Vabysmo have led analysts at SVB Leerink to slash their 2027 U.S. sales estimates for the macular degeneration blockbuster from $4.6 billion to $3.4 billion.
Rating:
0.0
Views:
69
Likes:
1
Library:
1
Rate This Post
-
Education
-
Communication
-
Entertainment
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value